Gates Package — page 27

Efficacy ot ravipiravir in mice intected with EBOV 1) Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model Oestereich L et al. Antiviral Res. 2014 105:17-21. T-705 T-705 300 mg/(kg x d) 300 mg/(kg x d) No treatment days 6 to 13 days 8 to 14 n=10 are on =5 ns. n=5 100. H00- == 50+ 50: a 0- 1--+--.--+ 0. -- +r 0. ----+ hie n.s. 8. ca ca Virus titer in blood (Log,, FFU/m!) ES » » 20] Day post infection 20] oO Day post infection Day post infection - Zaire EBOV Mayinga 1976 - IFNAR-/- C57BL/6 mice - Dose regimen: 150mg/kg BID, 8 days - Treatment was initiated at Day 6 or 8 post infection 2) Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Smither SJ et al. Antiviral Res. 2014 104:153-155. ' t Percent survival untreated 0.5% CMC o 4 5 26 27 28 20 30 Days post aerosol challenge -EBOV E718 - IFNAR-/- A129 mice - Dose regimen: 150mg/kg BID, 14 days - Treatment was initiated 1 hr after the infection In lethal mouse models, favipiravir gave 100% protection against EBOV infection at 150mg/kg BID.